Equities

Ascentage Pharma Group International

Ascentage Pharma Group International

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)44.30
  • Today's Change-1.15 / -2.53%
  • Shares traded700.00
  • 1 Year change+73.39%
  • Beta1.2517
Data delayed at least 15 minutes, as of Nov 13 2024 01:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 3 analysts offering 12 month price targets for Ascentage Pharma Group International have a median target of 47.76, with a high estimate of 54.72 and a low estimate of 40.79. The median estimate represents a 8.04% increase from the last price of 44.20.
High23.8%54.72
Med8.0%47.76
Low-7.7%40.79

Earnings history & estimates in CNY

Ascentage Pharma Group International reported annual 2023 losses of -3.28 per share on Mar 27, 2024.
Average growth rate+17.61%
More ▼

Revenue history & estimates in CNY

Ascentage Pharma Group International had revenues for the full year 2023 of 221.98m. This was 5.85% above the prior year's results.
Average growth rate+191.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.